Poly(ADP-ribose) polymerase inhibitors - Pipeline Insight, 2024

This “Poly(ADP-ribose) polymerase inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Poly(ADP-ribose) polymerase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Poly(ADP-ribose) polymerase inhibitors Understanding

Poly(ADP-ribose) polymerase inhibitors: Overview

Poly (ADP-ribose) polymerase inhibitors, which are often called PARP inhibitors, are targeted therapies that are used to treat cancer. PARP is a protein that has a role in cellular growth, regulation and cell repair which helps the cancer cells repair themselves and survive. The PARP inhibitor stops the cancer cells being repaired which causes the cells to die and so reduces tumor growth. In cancers where the tumor suppressor gene is faulty the cancer cells are repaired only by PARP. The PARP repair is incomplete which means the cancer cells DNA is repaired to a point where it just has a small amount of damage and the cancer cells are able to able to grow and divide. If the PARP did not repair the DNA then the cancer cells would have too much damage in its DNA so would trigger its own death. The PARP inhibitors act to stop the cancer cells DNA being repaired by PARP, so the damaged DNA stays at the critical level that causes cell to trigger its own death and therefore inhibits the growth of the tumor.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Poly(ADP-ribose) polymerase inhibitors R&D. The therapies under development are focused on novel approaches for Poly(ADP-ribose) polymerase inhibitors.

Poly(ADP-ribose) polymerase inhibitors Emerging Drugs Chapters

This segment of the Poly(ADP-ribose) polymerase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Poly(ADP-ribose) polymerase inhibitors Emerging Drugs

Talazoparib: Pfizer Talazoparib is an investigational anticancer drug called a PARP (poly ADP ribose polymerase) inhibitor, which is being evaluated in breast cancer patients with germline BRCA (g BRCA) mutations, as well as other cancer types with deficiencies in DNA damage repair (DDR). Talazoparib has not been approved by any Regulatory Authorities for the treatment of any disease. As a dual-mechanism PARP inhibitor, talazoparib is believed to both inhibit and trap the PARP enzyme, which may lead to heightenedcelldeath
Niraparib: Janssen Niraparib is an orally-administered selective PARP inhibitor that is currently being studied by Janssen for the treatment of patients with prostate cancer. In April 2016, Janssen entered a worldwide (except Japan) collaboration and license agreement with TESARO, Inc., for exclusive rights to niraparib in prostate cancer. In the U.S., niraparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Niraparib is currently marketed as ZEJULA® by TESARO, an oncology-focused business within GSK, devoted to providing transformative therapies to people facingcancer.

Poly(ADP-ribose) polymerase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Poly(ADP-ribose) polymerase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Poly(ADP-ribose) polymerase inhibitors

There are approx. 20+ key companies which are developing the Poly(ADP-ribose) polymerase inhibitors. The companies which have their Poly(ADP-ribose) polymerase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.

Phases

This report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Poly(ADP-ribose) polymerase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Poly(ADP-ribose) polymerase inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Poly(ADP-ribose) polymerase inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Poly(ADP-ribose) polymerase inhibitors drugs.

Poly(ADP-ribose) polymerase inhibitors Report Insights

• Poly(ADP-ribose) polymerase inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Poly(ADP-ribose) polymerase inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Poly(ADP-ribose) polymerase inhibitors drugs?
• How many Poly(ADP-ribose) polymerase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Poly(ADP-ribose) polymerase inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Poly(ADP-ribose) polymerase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Poly(ADP-ribose) polymerase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pfizer
• Janssen
• Jiangsu HengRui Medicine
• Jeil Pharmaceutical
• Rhizen Pharmaceuticals
• Rakovina Therapeutics
• Ribon Therapeutics
• Cybrexa Therapeutics
• Waverley Pharma
• Idience
• IMPACT Therapeutics
• Cephalon
• Shanghai De Novo Pharmatech
• Clovis Oncology
• BeiGene
• Abbvie
• AstraZeneca
• NanoGhost
• Allarity Therapeutics

Key Products

• Talazoparib
• Niraparib
• Fluzoparib
• Olaparib
• Veliparib
• Amelparib
• RP 12146
• CK 102
• 2X-121
• Pamiparib
• NG 1002
• SC 10914
• Rucaparib

Research programme: kt 2000 PARP inhibitors- Research programme: mono PARPinhibitors

• CBX 11
• Senaparib
• Venadaparib

This product will be delivered within 2-4 business days.